EUVIMEDEUVIMED entdecken
BeobachtungsstudieOpen Access · CC BY-NC 4.0

Serum Concentration Relationships of Candesartan in Migraine Prevention

Hedda Skogum Riise iD, Melanie Simpson iD, Ketil Arne Espnes iD, Erling Andreas Tronvik iD, Andreas Kattem Husøy, Lise R Øie, Anker Stubberud, Emil Kofoed, Aurora Harsvik Alstad, Hedda Hoff Hagen, Maren Guldteig Lien, Marie Larsen Stavseng und 2 weitere

Basic & Clinical Pharmacology & Toxicology · 2026

DOI: 10.1111/bcpt.70322 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift Basic & Clinical Pharmacology & Toxicology, 2026. Verfasst von Hedda Skogum Riise und 13 weiteren Autor:innen. Beteiligte Einrichtung: Norwegian Centre for Headache Research (NorHead), Norwegian University of Science and Technology (NTNU), Trondheim, Norway. Hauptthemen laut MEDLINE: Migraine Disorders, Tetrazoles, Benzimidazoles, Angiotensin II Type 1 Receptor Blockers. Die Arbeit nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: St. Olavs University Hospital.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Migraine is a common disabling disorder, and optimising affordable preventive treatments remains highly relevant. Candesartan is an effective and well‐tolerated preventive treatment, but little is known about its dose‐concentration–response relationships. We explored these relationships using data from the MigriNor study, a prospective observational cohort of adults with episodic or chronic migraine initiating oral preventive treatment. A total of 166 participants using candesartan were included (median age 35 years; 89% female). Participants completed a daily electronic headache diary during a 4‐week baseline and 12‐week follow‐up period with accompanying blood sampling. Dosing regimen was flexible. No differences in adverse drug reactions (ADRs) or treatment acceptability were observed between participants starting 4 versus 8 mg. Substantial interindividual variability in serum concentrations was observed. Higher serum concentrations were associated with lower odds of headache attacks (OR = 0.97, 95% CI = 0.96–0.98, p < 0.001) and migraine attacks (OR = 0.98, 95% CI = 0.97–0.99, p = 0.005). Interquartile ranges of serum concentrations among ≥ 30% and ≥ 50% responders were 62.9–141.2 and 62.3–129.3 nmol/L, respectively, suggesting preliminary therapeutic reference ranges. Serum concentration was not associated with ADRs or treatment acceptability. Interpretation is limited by the flexible dosing design, and studies with fixed dosing regimens are warranted.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Migraine DisordersTetrazolesBenzimidazolesAngiotensin II Type 1 Receptor BlockersHumansFemaleBiphenyl CompoundsAdultMaleProspective StudiesDose-Response Relationship, DrugMiddle AgedAdministration, Oral

Stichwörter der Autor:innen

candesartanmigrainepharmacokineticspreventiontherapeutic drug monitoring

Substanzen

TetrazolesBiphenyl CompoundsBenzimidazolescandesartanAngiotensin II Type 1 Receptor Blockers

Autor:innen und Institutionen

  • Norwegian Centre for Headache Research (NorHead), Norwegian University of Science and Technology (NTNU), Trondheim, Norway.
  • Department of Neurology and Neurophysiology, St. Olavs Hospital, Trondheim University Hospital, Trondheim, Norway.
  • Department of Neuromedicine and Movement Sciences, Faculty of Medicine and Health Sciences, Norwegian University of Science and Technology (NTNU), Trondheim, Norway.
  • Department of Public Health and Nursing, Faculty of Medicine and Health Sciences, Norwegian University of Science and Technology (NTNU), Trondheim, Norway.
  • Department of Clinical Pharmacology, St. Olavs Hospital, Trondheim University Hospital, Trondheim, Norway.
  • Faculty of Information Technology and Electrical Engineering, Norwegian University of Science and Technology (NTNU), Trondheim, Norway.

ORCID-Profile: Hedda Skogum Riise, Melanie Simpson, Ketil Arne Espnes, Erling Andreas Tronvik

Förderung

  • St. Olavs University Hospital

Zitieren

APA

Riise, H. S., Simpson, M., Espnes, K. A., Tronvik, E. A., Husøy, A. K., Øie, L. R., Stubberud, A., Kofoed, E., Alstad, A. H., Hagen, H. H., Lien, M. G., Stavseng, M. L., Sæther, E. R., & Wergeland, T. (2026). Serum Concentration Relationships of Candesartan in Migraine Prevention. Basic & Clinical Pharmacology & Toxicology. https://doi.org/10.1111/bcpt.70322

Vancouver

Riise HS, Simpson M, Espnes KA, Tronvik EA, Husøy AK, Øie LR, et al. Serum Concentration Relationships of Candesartan in Migraine Prevention. Basic & Clinical Pharmacology & Toxicology. 2026. doi:10.1111/bcpt.70322

BibTeX
@article{Riise2026,
  author = {Riise, Hedda Skogum and Simpson, Melanie and Espnes, Ketil Arne and Tronvik, Erling Andreas and Husøy, Andreas Kattem and Øie, Lise R and Stubberud, Anker and Kofoed, Emil and Alstad, Aurora Harsvik and Hagen, Hedda Hoff and Lien, Maren Guldteig and Stavseng, Marie Larsen and Sæther, Ella Rian and Wergeland, Tore},
  title = {Serum Concentration Relationships of Candesartan in Migraine Prevention},
  journal = {Basic & Clinical Pharmacology & Toxicology},
  year = {2026},
  doi = {10.1111/bcpt.70322}
}
Kostenlos starten →